Overexpression of 15-Hydroxyprostaglandin Dehydrogenase Inhibits A549 Lung Adenocarcinoma Cell Growth via Inducing Cell Cycle Arrest and Inhibiting Epithelial-Mesenchymal Transition

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• Aisner DL, Sholl LM, Berry LD, et al. The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium (LCMC2). Clin Cancer Res. 2018;24(5):1038–1047. doi:10.1158/1078-0432.CCR-17-228929217530
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Linnoila RI. The pathology of lung cancer–changing concepts and newer diagnostic techniques. Semin Oncol. 1988;15(3):215–225.2837828
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi:10.1016/S0140-6736(16)30958-827574741
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594. doi:10.4065/83.5.58418452692
   PubMed Web of Science ®Google Scholar
• Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358(11):1118–1128. doi:10.1056/NEJMoa070655018337602
   PubMed Web of Science ®Google Scholar
• Sporn JC, Kustatscher G, Hothorn T, et al. Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene. 2009;28(38):3423–3428. doi:10.1038/onc.2009.2619648962
   PubMed Web of Science ®Google Scholar
• Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–485. doi:10.1016/s0140-6736(00)82038-310841143
   PubMed Web of Science ®Google Scholar
• Zhang Y, Desai A, Yang SY, et al. TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science. 2015;348(6240):aaa2340. doi:10.1126/science.aaa234026068857
   PubMed Web of Science ®Google Scholar
• Tai HH, Cho H, Tong M, Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des. 2006;12(8):955–962. doi:10.2174/13816120677605595816533162
   PubMed Web of Science ®Google Scholar
• Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis. 2005;26(1):65–72. doi:10.1093/carcin/bgh27715358636
   PubMed Web of Science ®Google Scholar
• Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006;103(32):12098–12102. doi:10.1073/pnas.060323510316880406
   PubMed Web of Science ®Google Scholar
• Wolf I, O’Kelly J, Rubinek T, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006;66(15):7818–7823. doi:10.1158/0008-5472.can-05-436816885386
   PubMed Web of Science ®Google Scholar
• Li Y, Li S, Sun D, Song L, Liu X. Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: correlations with angiogenesis and prognosis. Oncol Lett. 2014;8(4):1589–1594. doi:10.3892/ol.2014.237125202373
   PubMed Web of Science ®Google Scholar
• Arima K, Komohara Y, Bu L, et al. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Cancer Sci. 2018;109(2):462–470. doi:10.1111/cas.1346729224225
   PubMed Web of Science ®Google Scholar
• Volpato M, Cummings M, Shaaban AM, et al. Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERalpha-positive breast cancer. Explor Target Antitumor Ther. 2020;1:355–371. doi:10.37349/etat.2020.0002133210098
   PubMedGoogle Scholar
• Li Y, Li J, Dong J, et al. 15-PGDH expression in gastric cancer: a potential role in anti-tumor immunity. Cancer Manag Res. 2020;12:7419–7426. doi:10.2147/CMAR.S24572632884353
   PubMed Web of Science ®Google Scholar
• Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A. 2004;101(50):17468–17473. doi:10.1073/pnas.040614210115574495
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx24728407145
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky113130476243
   PubMed Web of Science ®Google Scholar
• Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. 2010;2010:201367. doi:10.4061/2010/20136720811617
   PubMedGoogle Scholar
• Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995;20(10):435–439. doi:10.1016/s0968-0004(00)89095-78533159
   PubMed Web of Science ®Google Scholar
• Karimi Roshan M, Soltani A, Soleimani A, Rezaie Kahkhaie K, Afshari AR, Soukhtanloo M. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie. 2019;165:229–234. doi:10.1016/j.biochi.2019.08.00331401189
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang BC, Xiao Y. PI3K: a potential therapeutic target for cancer. J Cell Physiol. 2012;227(7):2818–2821. doi:10.1002/jcp.2303821938729
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. doi:10.21037/tlcr.2016.06.0727413711
   PubMed Web of Science ®Google Scholar
• Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. Curr Med Chem. 2017;24(15):1586–1606. doi:10.2174/092986732366616121411494827978798
   PubMed Web of Science ®Google Scholar
• He D, Li T, Sheng M, Yang B. Exonuclease 1 (Exo1) participates in mammalian non-homologous end joining and contributes to drug resistance in ovarian cancer. Med Sci Monit. 2020;26:e918751. doi:10.12659/MSM.91875132167078
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang Y, Wang Y, et al. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS One. 2014;9(5):e96989. doi:10.1371/journal.pone.009698924824601
   PubMed Web of Science ®Google Scholar
• Yu P, Huang B, Shen M, et al. p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene. 2001;20(4):484–489. doi:10.1038/sj.onc.120411311313979
   PubMed Web of Science ®Google Scholar
• Hu S, Zeng W, Zhang W, et al. KIAA0101 as a new diagnostic and prognostic marker, and its correlation with gene regulatory networks and immune infiltrates in lung adenocarcinoma. Aging. 2020;13(1):301–339. doi:10.18632/aging.10414433231570
   PubMedGoogle Scholar
• Chen H, Xia B, Liu T, Lin M, Lou G. KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells. Cancer Cell Int. 2016;16:74. doi:10.1186/s12935-016-0353-y27708548
   PubMed Web of Science ®Google Scholar
• Cheng Y, Li K, Diao D, et al. Expression of KIAA0101 protein is associated with poor survival of esophageal cancer patients and resistance to cisplatin treatment in vitro. Lab Invest. 2013;93(12):1276–1287. doi:10.1038/labinvest.2013.12424145239
   PubMed Web of Science ®Google Scholar
• Liu L, Chen X, Xie S, Zhang C, Qiu Z, Zhu F. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation. Hepatology. 2012;56(5):1760–1769. doi:10.1002/hep.2583422576474
   PubMed Web of Science ®Google Scholar
• Mamuya FA, Duncan MK. aV integrins and TGF-β-induced EMT: a circle of regulation. J Cell Mol Med. 2012;16(3):445–455. doi:10.1111/j.1582-4934.2011.01419.x21883891
   PubMed Web of Science ®Google Scholar
• Karar J, Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci. 2011;4:51. doi:10.3389/fnmol.2011.0005122144946
   PubMed Web of Science ®Google Scholar
• Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5(12):921–929. doi:10.1038/nrc175316341083
   PubMed Web of Science ®Google Scholar
• Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–132. doi:10.1016/j.semcancer.2019.07.00931323288
   PubMed Web of Science ®Google Scholar
• Dai Y, Tang Z, Yang Z, et al. EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients. Cell Cycle. 2018;17(19–20):2386–2397. doi:10.1080/15384101.2018.153451130328366
   PubMed Web of Science ®Google Scholar
• Nielsen FC, Jager AC, Lutzen A, Bundgaard JR, Rasmussen LJ. Characterization of human exonuclease 1 in complex with mismatch repair proteins, subcellular localization and association with PCNA. Oncogene. 2004;23(7):1457–1468. doi:10.1038/sj.onc.120726514676842
   PubMed Web of Science ®Google Scholar
• Engels K, Giannattasio M, Muzi-Falconi M, Lopes M, Ferrari S. 14-3-3 proteins regulate exonuclease 1-dependent processing of stalled replication forks. PLoS Genet. 2011;7(4):e1001367. doi:10.1371/journal.pgen.100136721533173
   PubMed Web of Science ®Google Scholar
• Yang G, Dong K, Zhang Z, et al. EXO1 Plays a Carcinogenic Role in Hepatocellular Carcinoma and is related to the regulation of FOXP3. J Cancer. 2020;11(16):4917–4932. doi:10.7150/jca.4067332626539
   PubMed Web of Science ®Google Scholar
• Lv W, Su B, Li Y, Geng C, Chen N. KIAA0101 inhibition suppresses cell proliferation and cell cycle progression by promoting the interaction between p53 and Sp1 in breast cancer. Biochem Biophys Res Commun. 2018;503(2):600–606. doi:10.1016/j.bbrc.2018.06.04629902451
   PubMed Web of Science ®Google Scholar
• Song B, Wang Y, Titmus MA, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010;9:96. doi:10.1186/1476-4598-9-9620433742
   PubMed Web of Science ®Google Scholar
• Stemmer V, de Craene B, Berx G, Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene. 2008;27(37):5075–5080. doi:10.1038/onc.2008.14018469861
   PubMed Web of Science ®Google Scholar
• Lin Z, Lin X, Zhu L, Huang J, Huang Y. TRIM2 directly deubiquitinates and stabilizes Snail1 protein, mediating proliferation and metastasis of lung adenocarcinoma. Cancer Cell Int. 2020;20:228. doi:10.1186/s12935-020-01316-632536816
   PubMed Web of Science ®Google Scholar
• Yang CM, Ji S, Li Y, Fu LY, Jiang T, Meng FD. β-Catenin promotes cell proliferation, migration, and invasion but induces apoptosis in renal cell carcinoma. Onco Targets Ther. 2017;10:711–724. doi:10.2147/ott.s11793328260916
   PubMed Web of Science ®Google Scholar
• He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–1512. doi:10.1126/science.281.5382.15099727977
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422–426. doi:10.1038/1888410201372
   PubMed Web of Science ®Google Scholar
• Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003;362(9379):205–209. doi:10.1016/S0140-6736(03)13910-412885482
   PubMed Web of Science ®Google Scholar